<DOC>
	<DOCNO>NCT01657578</DOCNO>
	<brief_summary>`` The principal aim trial determine minimum effective dose omeprazole neonate GERD objectively diagnose 24-h intra-oesophageal pH monitoring ( pHmetry ) , obtain short-term efficacy pHmetry control perform 72 hr ± 24 initiation omeprazole . The secondary objective study : ( 1 ) ass efficacy omeprazole upon pHmetry parameter , ( 2 ) characterize population pharmacokinetics pharmacogenetics omeprazole , ( 3 ) evaluate effect omeprazole upon oro-pharyngeal pH monitoring ( 4 ) ass short-term safety use omeprazole neonate . ''</brief_summary>
	<brief_title>Optimal Dosing Omeprazole Neonates</brief_title>
	<detailed_description>`` Omeprazole proton pump inhibitor increasingly prescribed neonatal population gastroesophageal reflux disease ( GERD ) complicate presence esophagitis . Although extensively evaluate adult , optimal dose schema , efficacy safety determine neonatal population prescription remain off-label . The study double blind trial design use Bayesian sequential analysis approach . The principle approach identify adequate drug dosage obtain level efficacy close possible predetermine target level efficacy population . In study , five different dosage omeprazole test ( 1 , 1,5 , 2 , 2,5 , 3 mg/kg/day ) target probability successful treatment 95 % chosen . To assess influence gestational age omeprazole 's efficacy , analysis stratify 3 group : ( 1 ) neonates less 32 week gestational age ( GA ) , ( 2 ) neonate bear 32 35 week GA , ( 3 ) neonates 36 week GA. A total maximum number 90 neonate expect include ( 30 neonate per group ) . Patients ' participation study end completion pHmetry control 72 ±24 hour omeprazole initiation . Patients study benefit management GERD non-pharmacological therapy adequate position use available thicken agent formula The pharmacologic agent authorise study treat GERD omeprazole . All available GERD treatment prescribe . ''</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>INCLUSION CRITERIA : Fullterm neonates preterm neonate postmenstrual age &gt; /= 35 week Presenting abnormal pHmetry ( = percentage entire record intraoesophageal pH &lt; 4 superior equal 5 % ) Patient must receive discontinuous oral feeding If proton pump inhibitor pharmacologic antireflux therapy already commence , withdraw 7 day baseline recording Inpatient Neonatal Intensive Care Unit Neonatology Unit Robert Debré University Hospital Both parent sign write informed consent form Affiliated social security EXCLUSION CRITERIA : Patients proton pump inhibitor ( PPI ) treatment discontinue PPI treatment le 7 day inclusion Patients acute gastrointestinal disease ( diarrhoea ) Patients present leucopenia thrombocytopenia ( value half normal value age ) Patients present aspartate alanine aminotransferase value twice upper limit normal Patients present renal hepatic failure Newborns presenting galactosemia , glucosegalactose malabsorption , deficiency lactase enzymes Coadministration atazanavir ritonavir Patients allergic omeprazole ingredient medicine</criteria>
	<gender>All</gender>
	<minimum_age>35 Weeks</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>neonate</keyword>
	<keyword>reflux disease</keyword>
	<keyword>population pharmacokinetics , omeprazole</keyword>
</DOC>